Arthritis Blood Test: 14-3-3 eta Ground-Breaking Data - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Arthritis Blood Test: 14-3-3 eta Ground-Breaking Data


Arthritis Blood Test: 14-3-3 eta Ground-Breaking Data

PR Newswire

VANCOUVER, May 29, 2014 /PRNewswire/ - Augurex Life Sciences Corp. announces a ground-breaking body of new data that will publish during the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology taking place June 11-14 in Paris. Investigators will present the studies listed in the schedule below, which to date along with other publications, represent over 2000 patients evaluated with the 14-3-3 eta blood test.

This follows the very recent publication of a study describing the novel mechanism by which 14-3-3 eta promotes disease. Rheumatoid arthritis (RA) develops from an interplay of several factors that lead to inflammation and joint damage, making it a particularly debilitative form of arthritis affecting about 1.5% of the population. Many of these factors have been known for decades, with the 14-3-3 eta protein now representing the most novel discovery of the past 7 years. The key is that 14-3-3 eta is a protein normally present inside cells, in all of us. However in patients who develop certain forms of arthritis 14-3-3 eta gets outside the cell and causes numerous harmful effects, implicating it directly in the disease process.

Augurex' Chief Scientific Officer, Dr. Anthony Marotta says "This protein is a scientist's dream because before its discovery in 2007, no one knew that it played a role in arthritis. It's not only exciting for Augurex and our international investigators to uncover the ways in which it causes disease, but also for patients and the rheumatology community at large." Dr. Marotta adds, "14-3-3 eta, and the related blood tests, will address so many autoimmune conditions which risk joint involvement, ultimately helping prevent disease development and progression. We can't wait to see what the world learns from this protein through international research and clinical use".

Dr. Marotta will be giving a web-based presentation on Friday, May 30th at 9:00 am PST entitled "How does the soluble mechanistic biomarker 14-3-3 eta assist in the management of Rheumatoid Arthritis?". The 14-3-3 eta blood test is available in the United States and will launch in Canada in the coming months.

Dr. Walter Maksymowych, the principal investigator of several 14-3-3 eta studies as well as the International Chair of the Outcomes Measures in Rheumatology Clinical Trials Soluble Biomarker Subcommittee and Medical Research Professor of Medicine and Rheumatologist at the University of Alberta, says "The body of evidence is now growing at such a rapid rate that we are seeing applications emerge in autoimmune diseases such as Ankylosing Spondylitis, where there are no useful diagnostic blood tests available." Dr. Maksymowych adds, "This protein can potentially change our perspective of disease mechanisms and open up a whole new area of research that could improve the lives of these patients."

List of 14-3-3 eta EULAR 2014 Conference Proceedings

Title

Date and Time

Location

14-3-3eta predicts radiographic progression in recent-onset polyarthritis patients

Presenter: Gilles Boire

Abstract # SAT0041

Poster Tour Presentation

June 13, 12:00 - 13:15

Room 251

Poster Presentation

June 14, 10:15 - 12:00

Poster area A, level 1

 

93% of early RA patients are positive for 14-3-3eta markers and 14-3-3eta auto-antibodies inform a favourable prognosis, irrespective of RF or ACPA status

Presenter: Dirkjan van Schaardenburg

Abstract # FRI0226

Poster Tour Presentation

June 14, 10:30-11:45

Level 3

Poster Presentation

June 13, 11:45-13:30

Poster area D, level 4

 

Auto-antibodies to a specific 14-3-3eta epitope is a marker of ankylosing spondylitis, is associated with SIJ inflammation and predicts radiographic progression

Presenter: Walter Maksymowych

Abstract # THU0105

Poster Presentation

June 12, 11:45-13:30

Poster area A, level 1

14-3-3eta is an independent predictor of radiographic changes in early RA and higher titres inform a higher likelihood of joint damage progression

Presenter: Dirkjan van Schaardenburg

Abstract # THU0244

Poster Presentation

June 12, 11:45-13:30

Poster area D, level 4

Evaluation of serum 14-3-3eta levels in a Japanese RA cohort treated with tocilizumab

Presenter: Akira Sagawa

Abstract # THU0226

Poster Presentation

June 12, 11:45 to 13:30

Poster area D, level 4

Lower levels of 14-3-3eta predict DMARD-associated DAS remission at 1 year follow up

Presenter: Dirkjan van Schaardenburg

Abstract # FRI0002

Poster Presentation

June 13, 11:45-13:30

Poster area A, level 1

Serum 14-3-3eta predicts the risk of RA development and its higher titres are associated with higher risk

Presenter: Dirkjan van Schaardenburg

Abstract # SAT0037

Poster Presentation

June 14, 10:15-12:00

Poster area A, level 1

Levels of 14-3-3eta predict Good EULAR response to anti-TNF treatment in patients with rheumatoid arthritis

Presenter: Walter Maksymowych

Abstract # SAT0070

Poster Presentation

June 14, 10:15-12:00

Poster area A, level 1

14-3-3eta biomarker dynamics in CIA mark disease severity in a non-interventional study Abstract # AB0152

 Abstract


14-3-3eta clinical assays are equivalent and RF does not interfere with its quantitation Abstract # AB0941

 Abstract


SOURCE Augurex Life Sciences Corp.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here